We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSHP Shire to announce second quarter 2017 results Dublin, Ireland - July 18, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce second quarter 2017 earnings on Thursday August 3, 2017. Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT Live conference call for investors: Flemming Ornskov, MD, Chief Executive Officer and Jeff Poulton, Chief Financial Officer will host the investor and analyst conference call at 9:00 EDT / 14:00 BST. The details of the conference call are as follows: UK dial in: 0808 237 0030 or 020 3139 4830 US dial in: 1 866 928 7517 or 1 718 873 9077 International http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Acc Access ess_List.pdf Numbers: Password/Conf 96350792# ID: Live Webcast: http://investors.shire.com/presentations-and-reports/quarterly-re sults-and-presentations Replay: A replay of the presentation will be available for two weeks by phone and by webcast for three months. Replay information can be found on the Investor Relations section of Shire's website at http://investors.shire.com/. For further information please contact: Investor Relations Ian Karp ikarp@shire.com +1 781 482 9018 Robert Coates rcoates@shire.com +44 1256 894874 NOTES TO EDITORS About Shire Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology. Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest. www.shire.com This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Shire plc via Globenewswire
(END) Dow Jones Newswires
July 18, 2017 07:15 ET (11:15 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions